Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro
| Autor: | R, Yerushalmi, J, Nordenberg, E, Beery, O, Uziel, M, Lahav, D, Luria, E, Fenig |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Dose-Response Relationship
Drug Rhodamines Blotting Western Cell Cycle Antineoplastic Agents Apoptosis Breast Neoplasms Drug Synergism Enzyme-Linked Immunosorbent Assay Sarcoma Ewing In Vitro Techniques Flow Cytometry Combined Modality Therapy Piperazines Inhibitory Concentration 50 Pyrimidines Cell Line Tumor Benzamides Imatinib Mesylate Humans Cisplatin Phosphorylation Proto-Oncogene Proteins c-akt Cell Proliferation Fluorescent Dyes |
| Zdroj: | Experimental oncology. 29(2) |
| ISSN: | 1812-9269 |
| Popis: | Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells.Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis.Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells.STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|